Ruhrlandklinik University Hospital, Essen, Germany Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03482752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Interstitial and Rare Lung Disease Unit, Ruhrlandklinik University Hospital, Essen, Germany

Active Ingredients

Drugs in Phase 3 Trials (1)

Filgrastim (neupogen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 3)

Pulmonary Alveolar Proteinosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1